Ming Guo
Oprichter bij Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Actieve functies van Ming Guo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
 Jiangsu Yasheng Pharmaceutical Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong. | Operationeel Directeur | 01-01-2009 | - |
| Oprichter | 01-01-2009 | - | |
| Sino-American Biotechnology & Pharmaceutical Professional | Oprichter | - | - |
| Corporate Officer/Principal | - | - | |
| The BayHelix Group | Corporate Officer/Principal | - | - |
| Ascentage International Ltd. | Directeur/Bestuurslid | - | - |
Loopbaan van Ming Guo
Eerdere bekende functies van Ming Guo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Operationeel Directeur | 01-05-2009 | 31-10-2021 |
| Oprichter | 01-05-2009 | 31-10-2021 | |
| PORTON PHARMA SOLUTIONS LTD. | Directeur/Bestuurslid | 01-10-2012 | 22-03-2016 |
| Independent Dir/Board Member | 01-10-2012 | 22-03-2016 | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01-03-2005 | 01-01-2010 |
| University of California San Diego | Corporate Officer/Principal | - | - |
| MONSANTO | Corporate Officer/Principal | - | - |
Opleiding van Ming Guo
| University of California San Diego | Doctorate Degree |
| Beijing Normal University | Undergraduate Degree |
| Peking Union Medical College | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| China | 6 |
| Hongkong | 2 |
Operationeel
| Corporate Officer/Principal | 5 |
| Founder | 3 |
| Director/Board Member | 2 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 4 |
| Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PORTON PHARMA SOLUTIONS LTD. | Health Technology |
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Health Technology |
| The BayHelix Group | |
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong. | Health Technology |
| Sino-American Biotechnology & Pharmaceutical Professional | |
| Ascentage International Ltd. |
